뇌전증약을 복용 중인 뇌전증 환자에서 코로나바이러스감염증-19 치료제를 사용할 때 고려사항
- Affiliated Author(s)
- 김근태
- Alternative Author(s)
- Kim, Keun Tae
- Journal Title
- 대한신경과학회지
- ISSN
- 2288-985X
- Issued Date
- 2022
- Keyword
- COVID-19; Epilepsy; Anticonvulsants; Drug interactions
- Abstract
- Several medications are approved to treat coronavirus disease 2019 (COVID-19) in Korea including nirmatrelvir/ritonavir, remdesivir, and regdanvimab. There is potential drug-drug interaction between antiepileptic drugs (AEDs) and the medications used to treat COVID-19. Several AEDs such as phenytoin, carbamazepine, phenobarbital, and primidone are strong cytochrome P450 inducers and can inhibit the drugs used for COVID-19. Particularly, these drugs are contraindicated with nirmatrelvir/ritonavir (Paxlovid®). There is a weaker drug-drug interaction between the AEDs and remdesivir. No significant interaction has been reported between the AEDs and molnupiravir. Pharmacokinetic interactions of the AEDs are important in effective management of COVID-19 in patients with epilepsy.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.